anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A method of irradiating provitamin D (for the production of vitamin D2, vitamin D3, tachysterol &c.) comprises agitating a provitamin D solution maintained at a temperature between room temperature and 50 DEG  C. while subjecting the solution to irradiation by ultra-violet light of a wavelength of 2500-3100 DEG  A.U. from a mantle-protected high-output ultra-violet source which is immersed in the solution. The provitamin may be ergesterol or 7-dehydrocholesterol and it may be dissolved in benzene, alcohol, ether, decalin, tetralin or toluene. Preferably, an inert gas such as carbon dioxide or nitrogen is introduced into the solution during the process.  The process may be carried out in an apparatus comprising a liquid-cooled container 13 of glass, earthenware, platinum, gold or enamelled metal into which the solution is introduced by a pipe 32, a mechanical stirrer 24, a pipe 28 for introducing <PICT:0617414/III/1> inert gas and a mercury arc 39 enclosed in a mantle 36 made of silica, "Corex" glass or like material which is transparent to ultraviolet light.  The arc may be cooled by passing air or the like through a side inlet 44 of a tube 43 which carries one of the arc leads 42, the air passing through channels in a positioning stopper 45 and out through a spacer 40.  According to modifications, several arcs may be used in one vessel and the arcs may be U-shaped or helical.ALSO:Vitamin D2, vitamin D3, tachysterol, &c. are prepared from provitamin D (e.g. ergesterol or 7-dehydrocholesterol) by agitating a provitamin solution maintained at a temperature between room temperature and 50 DEG  C. while subjecting the solution to irradiation by ultra-violet light of a wavelength of 2500-3100 DEG  A.V. from a mantle-protected high-output ultra-violet source which is immersed in the solution. Suitable solvents for the provitamin are benzene, alcohol, ethers, decalin, tetralin and toluene.  Preferably, an inert gas such as nitrogen or carbon dioxide is introduced into the solution during the process.  According to an example, solvent (benzene) is removed by vacuum distillation in an atmosphere of carbon dioxide at the completion of irradiation.  Unreacted ergosterol is recovered by repeated leachings with methanolether (2 : 1).  The residue is reacted with a pyridine solution of 3,5-dinitrobenzoyl chloride to convert it into the 3,5-dinitrobenzoate which is extracted with methanol after the removal of pyridine &c.  The dry residue is refluxed with acetone and on cooling the 3,5-dinitrobenzoate of vitamin D2 is crystallized out.  The ester is hydrolysed with methanolic potassium hydroxide to obtain vitamin D2.
The overarching goal of the project is to provide New York City with the first strengths-based, equity-oriented, culturally responsive, and cost-efficient suite of measurement and caregiver-oriented tools designed to boost healthy brain development by both assessing and strengthening the quality of caregiver-infant/toddler relationships. The primary goal of the study is to evaluate the effectiveness of the I-T CHILD-informed ECMHC on the caregiver beliefs and teaching practices. The secondary goal is to assess whether changes in caregiver beliefs and teaching practices are associated with children's developmental outcomes.

This project is Phase 2 (RCT) of an earlier proof-of-concept of the I-T CHILD (Phase 1). Phase 2 evaluates the I-T CHILD's application in early childhood mental health consultation services provided to family/group family child care programs. Phase 2 consists of the following main activities: (1) training and certification of early childhood mental health consultants from various NY-based agencies on the I-T CHILD Tool; (2) random assignment of child care providers into treatment (those receiving standard practice early childhood mental health consultation but enhanced with the I-T CHILD as a framework for consultation) and waitlist-control groups (no intervention until the end of the evaluation period); (3) provision of I-T CHILD resources to child care providers (user-friendly tips on how to strengthen their relationships with children and families); and (4) data collection (pre-test, post-test, 3-month follow-up). Data to be collected will include caregiver self-report surveys, caregiver ratings of children, observations (live or remote, depending on COVID-19 guidelines), and amount of language used in the program using LENA technology. Additionally, qualitative data will be collected from consenting participants through phone (or Zoom) interviews, depending on participant preferences.
Patients who are receiving or seeking medical care at University of Pittsburgh Medical Center CMI practices are given the GAD7(anxiety) and SF-12(quality of life) as a part of routine medical care. Patient scores become part of the EMR (Epic). A best practice alert will be generated for patients in the age range of 20-65 (inclusive) and in the targeted GAD7 score range (GAD7 ≥5) to prompt the provider to obtain consent. Within 2-4 weeks after consent, a UPMC research team member will administer via phone a brief, approximately 10 minute questionnaire for patients who score ≥10 on the GAD7 questionnaire and have signed consent. This DSM5 cross-cutting measure level 1 is a validated screening tool capturing primary psychiatric symptoms present across a range of disorders. A secure database will be maintained within the UPMC firewall where all patient information will be de-identified. Routine care safety protocols are in place if a patient's anxiety/stress worsens. At 6,12,18, and 24 months post-consent, the research team will contact the patient by phone to complete routine questionnaires (GAD7 and SF-12) if questionnaires have not been completed in clinic at an appointment or via the patient portal, MyUPMC. As part of the study, the patient will complete the Medical Utilization/Follow up questionnaire by phone with the research team at the 6, 12, 18, and 24 month time points. If the patient had any behavioral health treatment the research team will also ask the Helpfulness Questionnaire at the six month time point. In addition to these questionnaires, the research team will access Epic records to understand medical utilization.

CARe will provide the information from the medical record.
12-Oxo-phytodienoic acid reductases (OPRs) perform vital functions in plants. However, few studies have been reported in sugarcane (Saccharum spp.), and it is of great significance to systematically investigates it in sugarcane. Here, 61 ShOPRs, 32 SsOPRs, and 36 SoOPRs were identified from R570 (Saccharum spp. hybrid cultivar R570), AP85-441 (Saccharum spontaneum), and LA-purple (Saccharum officinarum), respectively. These OPRs were phylogenetically classified into four groups, with close genes similar structures. During evolution, OPR gene family was mainly expanded via whole-genome duplications/segmental events and predominantly underwent purifying selection, while sugarcane OPR genes may function differently in response to various stresses. Further, ScOPR2, a tissue-specific OPR, which was localized in cytoplasm and cell membrane and actively response to salicylic acid (SA), methyl jasmonate, and smut pathogen (Sporisorium scitamineum) stresses, was cloned from sugarcane. In addition, both its transient overexpression and stable overexpression enhanced the resistance of transgenic plants to pathogen infection, most probably through activating pathogen-associated molecular pattern/pattern-recognition receptor-triggered immunity, producing reactive oxygen species, and initiating mitogen-activated protein kinase cascade. Subsequently, the transmission of SA and hypersensitive reaction were triggered, which stimulated the transcription of defense-related genes. These findings provide insights into the function of ScOPR2 gene for disease resistance.
Plants are constantly challenged with numerous adverse environmental conditions, including biotic and abiotic stresses. Coordinated regulation of plant responses requires crosstalk between regulatory pathways initiated by different external cues. Stress induced by excessiveness or deficiency of nutrients has been shown to positively or negatively interact with pathogen-induced immune responses. Also, colonization by arbuscular mycorrhizal (AM) fungi can improve plant nutrition, mainly phosphorus and resistance to pathogen infection. The proposed review addresses these issues about a new question that integrates adaptation to nutrient stress and disease resistance. The main goal of the current review is to provide insights into the interconnected regulation between nutrient signaling and immune signaling pathways in rice, focusing on phosphate, potassium and iron signaling. The underpinnings of plant/pathogen/AM fungus interaction concerning rice/M. oryzae/R. irregularis is highlighted. The role of microRNAs (miRNAs) involved in Pi (miR399, miR827) and Fe (miR7695) homeostasis in pathogenic/symbiotic interactions in rice is discussed. The intracellular dynamics of membrane proteins that function in nutrient transport transgenic rice lines expressing fluorescent protein fusion genes are outlined. Integrating functional genomic, nutritional and metal content, molecular and cell biology approaches to understand how disease resistance is regulated by nutrient status leading to novel concepts in fundamental processes underlying plant disease resistance will help to devise novel strategies for crop protection with less input of pesticides and fertilizers.
BACKGROUND: Chronic pain often clusters in families, where parents and their offspring both experience chronic pain conditions. Young children of parents with irritable bowel syndrome (IBS) represent an at-risk group for the development of abdominal pain, disability, and excess health care visits in later childhood. Parental solicitous responses to children's expressions of discomfort and maternal modeling of their own illness behavior contribute to a greater focus on somatic sensations, leading to illness behaviors in children. This randomized controlled trial will test the effectiveness of an early preventive web-based psychosocial intervention (REACH)[TM] vs. an educational web-based safety comparison condition delivered to parents with IBS to alter parental responses and lead to improved child health and decreased health care costs.
METHODS: Parents with IBS who have children ages 4-7 years are recruited via community-based approaches (e.g., social media advertisements, school electronic distribution, research networks) and health care providers. The target sample is 460 parents randomized to REACH, a web-based social learning and cognitive behavior therapy (SLCBT) intervention or an educational web-based safety comparison condition (EC). Participants will be assessed at baseline, 6-week (immediate post-intervention), 6-month, 12-month, and 18-month follow-up periods (months post-completion of intervention). The primary outcome is change in parental solicitous/protective behaviors. Secondary outcomes include parent risk and protective factors, child health and symptom outcomes, and health care utilization and cost savings.
DISCUSSION: This study adapts a validated, parent-delivered intervention to treat chronic pain in children to a web-based application designed to prevent the development of chronic pain in very young, high-risk children. If successful, this strategy can both prevent adverse sequelae of this condition from developing as well as be widely accessible. Furthermore, the availability of a prevention model for parent training could result in significant short- and long-term health benefits across a broad spectrum of conditions.
TRIAL REGISTRATION: ClinicalTrials.gov NCT05730491. Registered on February 15, 2023.
It is experimental research with pre-post repeated measure with a control group. The subjects are randomised either in the intervention group (Gr PRORO-UL) or the control group (Gr CHU-CP). The assessor is blinded to the randomisation. Both groups receive their program at the first assessment at three months post-ACL-surgery. They are strongly encouraged to continue their follow-up in physiotherapy to ensure the program is suitable to their individual progression. The participants are assessed again at 4, 5, 6 and 9 months post surgery to measure their progression. A weekly journal sent by e-mail is to be filled to ensure the subjects train according to their program attribution. It is a randomised control trial with a blinded assessor.
This is a randomized phase II trial for patients with HER2 negative primary BC who after completing (neo) adjuvant chemotherapy and surgery have detectable CTC(s) in peripheral blood (see eligibility criteria for details). Eligible patients will be randomized in 1:1 ratio to either the trastuzumab arm or the observation arm. Patients randomized to the trastuzumab arm will receive a total of 6 intravenous (IV) administrations every 3 weeks (loading dose 8 mg/kg IV and 5 cycles at 6 mg/kg every 3 weeks). Patients randomized to observation arm shall be observed for 18 weeks. Left ventricular ejection fraction (LVEF) assessment (MUGA and/or ECHO) will be done at baseline for all patients to be randomized. The next LVEF assessments of weeks 9 and week 18 will be done only in patients randomized to trastuzumab arm. Patient registered but with CTC negative result will not be followed-up.
Coated senna extract granules are described, which comprise senna extract with 20% sennosides, Eudragit® L-100 and Eudragit® L30 D-55. The granulation process comprises processing the senna extract with Eudragit® L-100 solution in isopropyl alcohol, this solution being prepared twice, in equal quantities each time, and each solution is divided into 2 equal parts. The senna extract granulate is obtained by mixing the extract with one of said solutions, kneading and drying the granules. The resulting dry granules are mixed, again, with another of the Eudragit® L-100 solutions, kneaded and dried. This operation is repeated until all the solutions are used up. The resulting final granules are coated with a solution of Eudragit® L30 D-55 and polyethylene glycol and a solution of talc in purified water. Furthermore, the preparation of a jelly formulation that comprises the coated granules is described.
Accurate blood pressure (BP) measurement plays an important role in peripartum care as it is essential in detecting hypertensive disorders in pregnancy and medical decision making during the pregnancy. The cuff and bladder size have been highlighted as an important factor affecting the accuracy of BP measurement. Current international BP measurement recommendations are based on mid-arm circumference (MAC) assuming the arm is cylindrical in shape. However, evidence have shown a mismatch between these sizes, leading to BP overestimation or underestimation in obese patients. This is because the shape of the arm is a truncated cone instead of a cylinder, and the cuff will expand irregularly during inflation thus yielding inaccurate BP measurements. This is especially evident in Asian pregnant patients whereby no available guideline can recommend a suitable cuff for parturients with different MAC. Nexfin is a finger cuff device that can be a suitable alternative BP measurement device for such patients. In this study 300 parturients will be recruited in third trimester and undergoing nonemergent caesarean section in KKH. Patients' arm and finger sizes will be measured, and their user experience on current practices on BP measurement. The arm measurements will help to identify the proportion of women that may require non-standard cuff sizes for BP measurement. A conicity index will be determined whether the MAC, finger measurement or BMI is the best clinical predictor. The finger measurements will also help to determine the proportion of women that may require non-standard cuff sizes on the Nexfin device for BP measurement. The knowledge gathered in this pilot study will be used to design future studies in which the accuracy of Nexfin will be compared with standard BP measurement, which in turn will improve BP detection, subsequent patient monitoring and satisfaction.
The invention relates to a vector used for displaying antigenic epitope by using hepatitis B virus core particles, an animal vaccine, and a preparation method thereof. According to the invention, a DNA artificial synthesis method is adopted, and a coding DNA sequence of amino acid necessary for hepatitis B virus core protein is synthesized. In the synthesis process, a coding DNA sequence of hepatitis B virus core protein true peptide 1-149 site amino acid is adopted as a framework; 79-82 site amino acid coding sequence in the framework is removed, and only coding DNA relevant to virus particle assembly is preserved; for facilitating the insertion of other antigenic proteins in the hepatitis B virus core particle protein, a segment of DNA sequence coding flexible peptide is specially inserted at a position of the 79-82 site amino acid, and three endonuclease sites are introduced into the sequence, such that gene operation is facilitated; the above synthesized DNA segment is cloned into a gene cloning vector pUC18, such that a special vector pZNVC used for displaying antigenic epitope is formed; a synthesized DNA segment of an antigenic protein gene or coding epitope is inserted into pZNVC, and fusion protein is expressed in prokaryotic organisms or eukaryotic organisms. 78 amino acids on N-end of hepatitis B virus and 68 amino acids on C-end of hepatitis B virus can be folded into two columnar bodies, such that building blocks used for assembling the core protein particle are formed; flexible peptide forms a bond connecting the two columnar bodies; and proteins inserted between the flexible peptide protrude on the surface of the viral particles. The flexible peptide is composed of a series of small amino acids without side chain, and has certain flexibility. The flexible peptide does not affect the hepatitis B virus core particle protein and antigenic protein in independently and respectively folding into natural molecular structures. pZNVC is used for displaying antigenic protein antigenic epitopes, such that the existence state of the antigenic epitopes on natural pathogen outer membrane can be simulated to a maximal extent.
Melanoma showcases a complex interplay of genetic alterations and intra- and inter-cellular morphological changes during metastatic transformation. While pivotal, the role of specific mutations in dictating these changes still needs to be fully elucidated. Telomerase promoter mutations (TERTp mutations) significantly influence melanoma's progression, invasiveness, and resistance to various emerging treatments, including chemical inhibitors, telomerase inhibitors, targeted therapy, and immunotherapies. We aim to understand the morphological and phenotypic implications of the two dominant monoallelic TERTp mutations, C228T and C250T, enriched in melanoma metastasis. We developed isogenic clonal cell lines containing the TERTp mutations and utilized dual-color expression reporters steered by the endogenous Telomerase promoter, giving us allelic resolution. This approach allowed us to monitor morpholomic variations induced by these mutations. TERTp mutation-bearing cells exhibited significant morpholome differences from their wild-type counterparts, with increased allele expression patterns, augmented wound-healing rates, and unique spatiotemporal dynamics. Notably, the C250T mutation exerted more pronounced changes in the morpholome than C228T, suggesting a differential role in metastatic potential. Our findings underscore the distinct influence of TERTp mutations on melanoma's cellular architecture and behavior. The C250T mutation may offer a unique morpholomic and systems-driven advantage for metastasis. These insights provide a foundational understanding of how a non-coding mutation in melanoma metastasis affects the system, manifesting in cellular morpholome.
Binding between parts of living mineralized tissue such as between a tooth and the jaw bone is induced with a composition containing mammalian enamel matrix isolated from tooth germs and a carrier such as water, and optionally an adhesive containing fibrinogen, factor XIII and thrombin. The enamel matrix is a precursor to tooth enamel and induces binding by forming cementum tissue. The enamel matrix may be obtained from bovine or porcine species. The composition is particularly applicable in dental therapies including loosening of teeth due to periodontitis, transplantation of teeth or in reintroduction of teeth disconnected by accident. The composition may also be used for healing of artificial implants such as tooth implants and implants of skeletal replacements such as artificial hip joints. In the case of a dislocated tooth, the composition is applied to a surface of the tooth root and the tooth is put back into its alveolus and lightly fixed for some weeks. In the treatment of periodontitis, a tooth root surface is exposed by incision, the surface is cleaned, the composition is applied to the cleaned root surface and the incision is closed and optionally stitched to promote healing.
Disclosed are an ABA-type triblock copolymer based on a molecular glue, synthesis therefor, and use thereof. The structural formula of the copolymer is selected from the Formula (I). The copolymer of the present invention can be used to prepare a self-assembled medicine-carrying micelle. The present invention is based on the hydrophilicity of polyethylene glycol and chitosan of a low molecular weight, and on the hydrophobicity of polylactic acid, polycaprolactone, lauric acid, and stearate. Single chains of molecular glue having hydrogen bond sequence-selectivity are separately introduced into known macro-molecular polymers, such that under certain conditions, two complimentary single chains can form a molecular glue. A series of amphiphilic triblock copolymers can thereby effectively synthesized. Additionally, the molecular glue introduced contains a disulfide bond, and the copolymer is therefore sensitive to oxidoreduction. The raw material agents for the synthesis of the present invention can be easily obtained, the conditions are temperate, and the synthesis process contains only conventional chemical reactions and is suitable for large-scale production.
The invention discloses Chinese herbal medicine health-care wine for enhancing the sexual function and a production method thereof. Many kinds of Chinese herbal medicine with effects of nourishing liver and kidney, strengthening muscles and bones, astringing vital essence, curing collapse, invigorating and the like are selected to produce an efficient Chinese herbal medicine health-care wine product for enhancing the sexual function through a microwave assisted water soaking and wine soaking two-step method. The product is brownish-red and transparent and does not have suspended matters and precipitates. The product is soft and mellow, makes people comfortable and refreshing, and has harmonious tastes and a typical ginseng taste. According to the method, Chinese herbal medicine plants and fructus psoraleae are adopted as raw materials, the potential safety hazard of animal Chinese herbal medicine health-care wine is avoided, and the product is environmentally friendly, safe and has small side effects. Various Chinese herbal medicine plants are compatibly applied, and the effects of the Chinese herbal medicine health-care wine are increased through the interaction of the Chinese herbal medicine. The microwave assisted water soaking and wine soaking two-step method is adopted during the process, so that water-soluble active substances in the Chinese herbal medicine are effectively extracted, alcohol-soluble active substances in the Chinese herbal medicine are also effectively extracted, and the effects of the product are good.
Patients were randomly assigned to Esmolol Group. The drug was dispensed in 60ml \& 5ml syringes of 0.9% NaCl and 10mg/ml Esmolol. Investigators and patients were blinded to the group assignment.